The European Medicines Agency has published a draft transparency policy that sets out how the Agency intends to provide for greater clarity and openness in all areas of its operations.
The objectives of the transparency policy are:
- to apply a more proactive approach to transparency in the daily operations of the Agency;
- to further strengthen interaction with the Agency’s stakeholders;
- to promote co-operation on transparency issues within the European medicines network.
The Agency released the draft policy for public consultation between June and September 2009. The Agency is processing the comments received during the consultation.
The Agency has hosted two workshops to provide an opportunity for discussion on the draft policy with stakeholders.
The first workshop took place on 22 January 2009, and allowed attendees to express their initial thoughts and provide feedback on their understanding and expectations on the level of transparency of Agency activities. The Agency invited members from patients’, consumers’ and healthcare professionals’ organisations, learned societies and farmers’ unions to attend, as well as representatives from European pharmaceutical industry associations.
The workshop addressed issues concerning commercially confidential information was addressed with input from the joint European Medicines Agency/Heads of Medicines Agencies Group on Transparency and from the European Medicines Agencies Cooperation on Legal Issues (EMACOLEX).
A second workshop took place at the Agency on 19 October 2009.
Table of contents
- Transparency policy
- Guidance and recommendations from the Heads of Medicines Agencies and the European Medicines Agency
|Document(s)||Language||Status||First published||Last updated||Effective Date|
|The European Medicines Agency transparency policy draft for public consultation||(English only)||draft: consultation closed||19/06/2009|